RAPPIENE: studio retrospettivo RWE per valutare l'impatto del cenobammato sull'utilizzo delle risorse sanitarie
Valutazione retrospettiva dell'utilizzo delle risorse sanitarie del cenobamato (HCRU) nella gestione di convulsioni non controllate di insorgenza focale: uno studio retrospettivo di revisione dei grafici
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
Germany
-
Freiburg im Breisgau, Germany, Germania
- Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg
-
Hamburg, Germany, Germania
- Epileptologicum
-
Kork, Germany, Germania
- Diakonie Kork, Epilepsiezentrum
-
-
-
-
Netherlands
-
Heeze, Netherlands, Olanda
- Kempenhaeghe - Academisch Centrum voor Epilepsie
-
-
-
-
UK
-
Glasgow, UK, Regno Unito
- Institute of Neurosciences NHS Greater Glasgow and Clyde
-
Wolverhampton, UK, Regno Unito
- Epilepsies - The Royal Wolverhampton NHS Trust
-
-
-
-
Spain
-
Barcelona, Spain, Spagna
- Epilepsy Unit - Neurology Department Valle de Hebron Hospital
-
Madrid, Spain, Spagna
- Epilepsy Unit of the Neurology Department of the Hospital Clínico San Carlos
-
Valencia, Spain, Spagna
- Consorcio Hosp. General Universitario Valencia
-
-
-
-
Switzerland
-
Zurich, Switzerland, Svizzera
- Department of Neurology, University Hospital Zurich
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more anti-seizure medications (ASMs), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and healthcare resources utilization (HCRU) (if any) prior to cenobamate starting date.
Descrizione
Inclusion Criteria:
- Male and female patients of any ethnic origin ≥18 years old at index date;
- Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
- Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
- Patients with at least 6 months of data coverage in the medical records prior to the index date;
- Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
- Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.
Exclusion Criteria:
- Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
- Patients who started cenobamate within an EAP;
- Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
- Patients with specific syndrome (e.g. LGS and Dravet);
- Pregnancy or lactation;
- Patients without self-judgement ability;
- Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);
- Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: RETROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
|---|
|
Adult patients affected by epilepsy with focal-onset seizures
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more ASMs (anti-seizure medications), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and HCRU (if any) prior to cenobamate starting date. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU, will be collected the number of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU,will be collected the length of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related outpatient visits (OP) during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related emergency room (ER) visits; |
0-12 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Switch/add-on of other ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the dose of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the number of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Time to discontinuation of ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care
Lasso di tempo: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care, the number of epilepsy/epilepsy treatment related emergency care, ambulance use, the number of outpatient visits with neurologists, and the number of epilepsy specialist nurses' intervention will be collected; |
0-12 months
|
|
Effectiveness of cenobamate used as adjunctive therapy
Lasso di tempo: 0-12 months
|
To evaluate the effectiveness of cenobamate used as adjunctive therapy, seizure frequency at baseline and at routinely scheduled follow-up visits, till the end of observation will be collected. For comparability, seizure frequency will be extrapolated per month (28 days); |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related surgery
Lasso di tempo: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related surgery the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on comorbidity-related healthcare resources utilization (HCRU)
Lasso di tempo: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on comorbidity-related HCRU, the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions
Lasso di tempo: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions, the number of phone calls/virtual interventions will be collected. |
0-12 months
|
|
Safety of cenobamate used as adjunctive therapy
Lasso di tempo: 0-12 months
|
To evaluate safety of cenobamate used as adjunctive therapy, the number, type and severity of, adverse events, adverse drug reactions will be collected. Moreover, changes in the number, type, dose of concomitant medications other than anti-seizure medications will be collected over the duration of the study. |
0-12 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 169(A)AV23432
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .